1760 Bailing-Fujin | Announcement on the Progress of Nephoxil (Ferric Citrate Capsule) Application for Inclusion in China's National Reimbursement Drug List

Date of Announcement: August 7, 2026 Date of Statement: August 6, 2026 Time of Statement: 18:01:55 Company Code: 1760 Company Name: Bailing-Fujin Biotechnology Co., Ltd. Subject: Announcement regarding the follow-up development of the application for the inclusion of our new drug Nephoxil (ferric citrate capsule) in the adjustment of China's National Medical Insurance Catalogue Relevant Clause: Clause 51 Factual Date: August 6, 2026

Explanation: 1. Factual Date: August 6, 2026 2. Company Name: Bailing-Fujin Biotechnology Co., Ltd. 3. Relationship with Company (enter '本公司' or 'subsidiary'):本公司 (Our Company) 4. Cross-shareholding Ratio: Not applicable 5. Reason for Occurrence: On June 5, 2026, we announced that in response to the application timeline for adjustments to China's National Medical Insurance Catalogue, the Board of Directors resolved to sign an authorization letter appointing Weigao Peritoneal Dialysis Technology (Weihai) Co., Ltd. as the responsible entity and exclusive agent within mainland China for our new drug Nephoxil (ferric citrate capsule), authorizing them to handle administrative procedures related to national medical insurance, including online registration, data submission, price negotiations, and market access preparations.

On August 6, 2026, we received notification from the authorized agent that Nephoxil (ferric citrate capsule) did not pass the expert review stage of the current year's adjustment to China's National Medical Insurance Catalogue and therefore did not proceed to the subsequent medical insurance price negotiation process.

6. Response Measures: The company will continue to monitor developments in China's national medical insurance policies and market conditions, and will jointly assess future arrangements with local market partners based on actual circumstances.

7. Other Matters to be Disclosed (If the subject of the event or resolution is a publicly listed company or above, this material information also qualifies under Article 7, Paragraph 9 of the Enforcement Rules of the Securities Trading Act as a matter having a significant impact on shareholder rights or securities prices): (1) The failure to pass the expert review means that Nephoxil (ferric citrate capsule) did not advance to the subsequent price negotiation stage of the current year's adjustment to China's National Medical Insurance Catalogue. This review outcome does not affect the validity of the product’s existing drug registration certificate or its eligibility for marketing and sale in China. (2) The product has not yet generated any related sales revenue. This matter currently has no immediate material impact on the company's financial condition or operations. (3) New drug development involves long timelines, high investment costs, and does not guarantee success, which may expose investors to risks. Investors should exercise careful judgment and prudence when investing.